General
Preferred name
AVANBULIN
Synonyms
BAL27862 ()
Avanbulina ()
Avanbuline ()
BAL-27862 ()
P&D ID
PD164515
CAS
798577-91-0
Tags
available
drug candidate
Drug Status
investigational
Max Phase
2.0
Drug indication
Neoplasm
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Avanbulin (BAL27862) is a potent, Colchicine site-binding, tubulin assembly inhibitor. Avanbulin inhibits tubulin assembly at 37 ¡ãC with an IC50 of 1.4 ¦ÌM. Avanbulin binds to tubulin with an apparent Kd value of 244 nM. Avanbulin can be used for the research of cancer and cell division[1][2][3][4].
DESCRIPTION BAL27862 is a novel synthetic potent inhibitor of tubulin polymerization that induces cancer cell death. BAL27862 is a novel microtubule-destabilizing drug that is currently undergoing phase I clinical evaluation as the prodrug BAL101553. (BOC Sciences Bioactive Compounds)
Compound Sets
3
BOC Sciences Bioactive Compounds
bal27862-cas-798577-91-0-item-84-462684
ChEMBL Drugs
CHEMBL3422109
MedChem Express Bioactive Compound Library
HY-106008
External IDs
11
Properties
(calculated by RDKit )
Molecular Weight
387.14
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
4
cLogP
2.88
TPSA
135.65
Fraction CSP3
0.15
Chiral centers
0.0
Largest ring
6.0
QED
0.28
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Cell Cycle/DNA Damage
cytoskeleton
Target
Microtubule/Tubulin
Source data